At least one in five people has obesity in each US state
By
HealthDay News
Sep 12, 2024
CDC data show that in 23 states, 35% or more of the population is now obese.
Insulin resistance linked to risk for more than 30 diseases
By
Haymarket Media
Sep 09, 2024
Twenty-six positive and five negative correlations were seen, as well as a link between insulin resistance and all-cause mortality in women.
Chronic diabetes complications bidirectionally linked to mental health disorders
By
Haymarket Media
Aug 28, 2024
The findings were seen across the life span and irrespective of diabetes type.
FDA expands approval of Omnipod 5 insulin delivery system to include patients with type 2 diabetes
Aug 27, 2024
Omnipod 5 works in concert with a continuous glucose monitor to manage blood glucose with no daily injections and no finger pricks.
Risks for mortality, adverse heart, kidney events lower with tirzepatide for T2DM
Aug 12, 2024
The risks for all-cause mortality, adverse cardiovascular events, acute kidney injury and adverse kidney events were lower versus GLP-1 RA.
Study looks at effects of reducing intake of processed meat, unprocessed red meat
Jul 29, 2024
A 30% reduction in processed meat intake would lead to 352,900 fewer occurrences of type 2 diabetes and 92,500 fewer occurrences of cardiovascular disease.
Study: Professional medication review is a must when older adults want to scale back meds
By
Kristen Fischer
Jul 29, 2024
Many older adults want to cut back on taking multiple medications, or polypharmacy, but they need to talk to a clinician or pharmacist first, authors of a new report say.
Vitamin D suggested for children, seniors, those with high-risk prediabetes
Jun 10, 2024
No evidence was seen to support routine 25(OH)D screening in the general population.
Semaglutide cuts risk for kidney outcomes, death in CKD with T2DM
May 31, 2024
A reduction was seen in risk for clinically important kidney outcomes and death from cardiovascular causes.
ACP: Recommendations developed for newer type 2 diabetes medications
Apr 22, 2024
A strong recommendation was given for the addition of an SGLT-2 or GLP-1 agonist to metformin, and lifestyle modifications.